IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kyowa Kirin Co.,Ltd. Develops antibody medicines for oncology, nephrology, immunology, and allergy.	Japan	4151
KyungdongPharm Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.	South Korea	011040
KYUNG NAM PHARM.CO.,LTD. South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.	South Korea	053950
Kyverna Therapeutics, Inc. Developing CAR T-cell therapies for durable remission in autoimmune diseases.	United States of America	KYTX
Labiana S.A. Pharmaceutical CDMO for animal & human health with its own line of vaccines and generics.	Spain	LAB
Labocanna Spolka Akcyjna Cultivates and distributes medical marijuana and cannabinoid products for clinical and consumer use.	Poland	LCN
Labomar A CDMO developing custom supplements, medical devices & cosmetics for third-party clients.	Italy	LBM
Laboratorio Farmaceutico Erfo Full-service contract manufacturer of private label supplements and medical devices.	Italy	ERFO
Laboratorio Reig Jofre S.A. A pharmaceutical company making essential health products accessible in over 70 countries.	Spain	RJF
Laboratorios Farmaceuticos Rovi S.A. Integrated pharma firm developing prescription drugs and offering contract manufacturing services.	Spain	ROVI